Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

Interesting comment on SA's

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 14
Posts 1,513
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Bernstein Liebhard LLP Reminds Investors of its Investigation into Portola Pharmaceuticals, Inc., and Enco... PR Newswire (US) - 1/27/2020 1:46:00 PM
Shareholder Alert: Robbins LLP Announces Portola Pharmaceuticals, Inc. (PTLA) Sued for Misleading Shareholders Business Wire - 1/21/2020 3:51:00 PM
Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Portola Pharmaceuticals, ... Business Wire - 1/17/2020 7:17:00 PM
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Portola Pharmaceuticals, Inc.... Business Wire - 1/17/2020 4:01:00 PM
The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Portola Pharmaceuticals, Inc., (PTLA) Business Wire - 1/10/2020 6:41:00 PM
(PTLA) Alert: Johnson Fistel Launches Investigation into Portola Pharmaceuticals; Investors Encouraged to Contact Firm PR Newswire (US) - 1/10/2020 12:04:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/9/2020 4:20:56 PM
Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million PR Newswire (US) - 1/9/2020 4:01:00 PM
Schedule 13g Edgar (US Regulatory) - 1/8/2020 2:03:11 PM
Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020 PR Newswire (US) - 12/23/2019 8:30:00 AM
Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke PR Newswire (US) - 12/17/2019 8:30:00 AM
Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavi... PR Newswire (US) - 12/9/2019 3:21:00 PM
Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in H... PR Newswire (US) - 12/8/2019 12:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/21/2019 5:08:24 PM
Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians PR Newswire (US) - 11/15/2019 4:25:00 PM
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting PR Newswire (US) - 11/6/2019 10:07:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 5:12:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 4:14:01 PM
Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update PR Newswire (US) - 11/5/2019 4:00:00 PM
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 11/1/2019 4:30:00 PM
Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in ... PR Newswire (US) - 10/28/2019 9:00:00 AM
Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019 PR Newswire (US) - 10/15/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:21:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/2/2019 4:17:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/23/2019 6:33:32 AM
H2R   Tuesday, 12/04/18 10:46:35 AM
Re: None
Post # of 192 
Interesting comment on SA's

https://seekingalpha.com/news/3414289-portolas-cerdulatinib-continues-show-positive-action-mid-stage-lymphoma-study

Quote:
Fightdoctor

This was a positive study in a drug that may produce something for Portola investors. However, the main reason to be in this stock is for the drug Andexxa, the reversal agent for Eliquis and Xarelto. The drug is approved but the method of producing it, referred to as Gen 1 is inefficient. Portola is only offering this life saving drug to about 160 US hospitals at this time. Investors are awaiting two decisions. The CHMP decision for the European Union is due next week and the FDA approval decision of the Gen 2 method of producing is due by Dec. 31. Portola has stock piled over $300,000,000 of the Gen. 2 drug in anticipation of that approval. The drug is being manufactured by a very reliable Swiss company, Lonza. They have an excellent record of bringing drugs through regulatory processes.

The stock as been beaten down with a very large short interest. That has presented an uncommon opportunity to get in on a company at a low price.
I am a long term believer in Portola and Andexxa. There are lots of opinions as to when this company share price will take off and how high it will go. But, based on the action at the time of previous, less momentous, announcements I am expecting two large pops soon.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist